BioSpace News Archive

Frequency Therapeutics to Present 2022 Business and Pipeline Overview at the 40th Annual J.P. Morgan Healthcare Conference.

9 Meters Biopharma, Inc. today announced that the Company’s CEO, John Temperato along with other management team members will participate in the following conferences in January and invites investors to participate in virtual one-on-one meetings.

Akoya Biosciences, Inc. today announced that it will be virtually participating in the 40th Annual J.P. Morgan Healthcare Conference.

Apexigen, Inc. today announced the appointment of Francis Sarena as Chief Operating Officer.

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), announced today that it has received approval from the Serbian Medicines and Medical Devices Agency (ALIM) for its Clinical Trial Application (IND equivalent) to conduct a Phase IIb clinical trial with vafidemstat in patients with Borderline Personality Disorder (BPD) in Serbia.

Spero Therapeutics, Inc. (Nasdaq: SPRO), today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on the Phase 2 trial of SPR720, Spero’s investigational oral product candidate being developed for nontuberculous mycobacterial (NTM) disease.

Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Company is scheduled to participate in the upcoming 40th Annual J.P. Morgan Healthcare Conference.

Vaxart, Inc. announced that Andrei Floroiu, President and Chief Executive Officer, Dr. Sean Tucker, SVP and Chief Scientific Officer, and Dr. James Cummings, Chief Medical Officer, will participate in a virtual fireside chat at the H.C. Wainwright BioConnect Virtual Conference taking place January 10-13, 2022.

Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced the Company will present at the virtual 40th Annual J.P. Morgan Healthcare Conference at 9:00 a.m. ET / 6:00 a.m. PT on Tuesday, January 11, 2022.

Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, announced that the Company will be participating in the H.C. Wainwright BIOCONNECT Virtual Conference taking place January 10, 2022, through January 13, 2022.